Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USA.
Expert Opin Pharmacother. 2010 Apr;11(5):829-42. doi: 10.1517/14656561003645611.
Lenalidomide and other new agents are improving survival of multiple myeloma patients. This review describes current data on lenalidomide in myeloma and how the unique properties of lenalidomide may lend its use in new settings, such as maintenance and preventive therapy.
This review covers the activity of lenalidomide in multiple myeloma, efficacy in both newly diagnosed and relapsed/refractory patients, how to manage effectively common adverse events observed with lenalidomide, and its potential use in new settings based on clinical trials published up to 2009.
This review describes the mechanism of action of lenalidomide in myeloma which provides the basis for its clinical use in newly diagnosed, relapsed/refractory, and high-risk smoldering myeloma in combination with other agents. Strategies to reduce or effectively manage myelosuppression and thromboembolic events, the main adverse events associated with lenalidomide plus dexamethasone therapy, are also described.
Lenalidomide is an oral immunomodulatory drug that is highly effective in treating multiple myeloma, has a favorable safety profile and is now being evaluated as maintenance therapy, preventive therapy and in combination with other new agents.
来那度胺和其他新的药物正在改善多发性骨髓瘤患者的生存。这篇综述描述了目前在多发性骨髓瘤中来那度胺的数据，以及来那度胺的独特性质如何使其在新的环境中得到应用，如维持和预防治疗。
这篇综述涵盖了来那度胺在多发性骨髓瘤中的活性，在新诊断和复发/难治性患者中的疗效，如何有效地管理来那度胺观察到的常见不良反应，以及根据截至 2009 年发表的临床试验，其在新环境中的潜在用途。
这篇综述描述了来那度胺在骨髓瘤中的作用机制，为其在新诊断、复发/难治性和高风险冒烟骨髓瘤中与其他药物联合使用提供了依据。还描述了减少或有效管理骨髓抑制和血栓栓塞事件的策略，这些是与来那度胺加地塞米松治疗相关的主要不良反应。
来那度胺是一种口服免疫调节药物，在治疗多发性骨髓瘤方面非常有效，具有良好的安全性，目前正在作为维持治疗、预防治疗以及与其他新药物联合使用进行评估。
